An intervention program that coaches patients in stress management and goal setting, along with a digital app, helped ...

UCB and Biogen Inc. (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a Fc-free ...

The focus of this review, the CD40/CD40L costimulatory system, belongs to the TNF-TNF receptor superfamily, and will be discussed in the context of IBD pathogenesis. Comprehensive reviews on the ...

Dapirolizumab pegol was better than a placebo at controlling disease activity in systemic lupus erythematosus patients in a Phase 3 trial.

After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with ...

Analyst Rami Katkhuda of LifeSci Capital maintained a Buy rating on Eledon Pharmaceuticals (ELDN – Research Report), retaining the price ...

Eledon Pharmaceuticals (NASDAQ:ELDN – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued on Wednesday,Benzinga reports. They presently have a $16.00 ...

The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The ...

01 优时比和渤健公布了3期PHOENYCS GO研究的详细结果，显示dapirolizumab pegol与标准治疗联用显著改善中度至重度系统性红斑狼疮患者的疾病活动程度。 今日，优时比（UCB）和渤健（Biogen）公布了3期PHOENYCS ...

The 321-subject trial is comparing the anti-CD40L antibody to placebo on top of standard care in SLE patients, with the primary endpoint response on the BILAG 2004-based Composite Lupus Assessment ...

进入2024年第三季度后，不少大药企研发新一代药物与疗法的步伐加快，希望在未来几年内看见成效。实际上，大范围的专利悬崖正威胁或已蚕食了投资者的预期利润。除了重磅药物失去专利保护外，在一些疾病领域遇阻后，也在刺激制药公司押注新产品。